VPRO Viropro Inc (CE)

NEW YORK, NY – October 26, 2015 -- InvestorsHub NewsWire -- Small Cap Street makes the connection between sophisticated investors and high quality micro and small cap companies that are currently undervalued. We are an issuer of reports written by experienced financial analysts and who provide a straight forward assessment of profiled companies. They include stocks traded in the NYSE, NASDAQ, and OTCBB exchanges.

*Special Situation Alert Coming Tuesday, October 27^th, 2015*

Small Cap Street and several other large media providers will be profiling an exceptional growth company that has some similarities to our last 200% winner.

This company recently executed a large reverse merger and is flying way under the radar. With an extremely tiny float we are expecting this to be one of our best alerts ever.

Be ready at 9:45 am EST on Tuesday, October 27^th, 2015 by joining our group here: smallcapstreet.com

To receive profiles in real time, text "Street" to 25827

4 Brief Company Reports -

Viropro, Inc. (OTCBB: VPRO) through its subsidiaries, is engaged in the contract research, development, and manufacture of biotherapeutic proteins for the treatment of various diseases. The company is also involved in the transfer of its proprietary technologies for industrial production of biogeneric therapeutic proteins for the treatment of various diseases, such as cancer, diabetes, hepatitis, or multiple sclerosis.

VPRO has signed a non-binding Letter of Intent for the acquisition of NovaRx, a San pioneer in immuno-oncology, in an all-stock transaction that is expected to close by year-end. NovaRx has developed a method of activating the body's immune system to recognize and destroy cancer cells.  In a Phase II trial, the company demonstrated a significant improvement in survival for patients with non-small cell lung cancer. A Phase III trial did not achieve its desired endpoint.  The company's management believes that a properly designed and administered Phase III study will yield different results.

Kallo, Inc. (OTCQB: KALO) develops and delivers innovative, technologically advanced and turnkey healthcare solutions in the developing world and rural communities including infectious disease management, education and training programs. The company's mobile technology suite transforms the delivery of rural medicine, disease management, clinical globalization, and eHealth solutions.

KALO was recognized last month with the Frost & Sullivan 2015 Award for Emerging Market Innovation. This award recognizes Kallo's unique holistic approach to healthcare delivery. Kallo's modular approach caters to the specific healthcare needs of each region through a combination of polyclinics, mobile clinics, teaching institutions and telemedicine. This system is designed to serve such emerging nations as Guinea, Senegal, Nigeria, Peru, Brazil, Cameroon and Chad.

Urban Barns Foods Inc. (OTCQB: URBF) is a Canadian food producer growing fresh vegetables year round. Grown in a completely controlled environment, their vegetables are grown from non-GMO seeds and free of pesticide, herbicide, and fungicide. Controlled environment means no contact with the outside world, eliminating the possibilities of contamination and infection. The company specializes in leafy vegetables including lettuce and basil that are Kosher-certified.

URBF has undergone a restructuring of its executives this year making changes in the Chairman, CEO, and President and Directors positions. The company’s fiscal year ends July 31st. Recent financials indicate a drop in shareholder equity, primarily due to increased debt, and a better bottom line due to a significant cut in operating expenses.

Elite Pharmaceuticals, Inc. (OTCQB: ELTP) is a pharmaceutical company developing a pipeline of pharmacological abuse-deterrent opioid products and niche generic products. Elite owns generic and OTC products licensed to TAGI Pharma, Epic Pharma and Valeant Pharmaceuticals International with seven commercial products currently being sold.

The company has achieved positive top-line results from the Phase 3 pivotal trial of its lead opioid abuse-deterrent candidate, ELI-200, for the treatment of moderate to severe pain. There were no serious adverse events or deaths related to ELI-200 reported during the conduct of the trial. Elite intends to submit a New Drug Application to the U.S. Food and Drug Administration for abuse-deterrent ELI-200 by year-end.

Forward-Looking Disclaimer   
This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward- looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.   

Compliance Procedure   
Content is researched, written and reviewed on a best-effort basis by a 3rd party research analyst. However, we are only human and may make mistakes. This report was prepared for informational purposes only.  A full disclaimer can be found by viewing the full analyst report. We do not engage in high frequency trading or hold any positions of profiled company.

For more information and services provided beyond this release please use contact information provided below. If you notice any errors or omissions, please notify us below.

Source: Small Cap Street

Contact: editor@smallcapstreet.com
 

Viropro (CE) (USOTC:VPRO)
Historical Stock Chart
From Nov 2024 to Dec 2024

Viropro (CE) (USOTC:VPRO)
Historical Stock Chart
From Dec 2023 to Dec 2024